Use of Bismuth in Irritable Bowel Syndrome

Use of Bismuth in Irritable Bowel Syndrome

Aim. An evidence review on use of bismuth in irritable bowel syndrome.Key points. Irritable bowel syndrome (IBS) is a common functional disorder significantly impacting the quality of life and social status, i.a., through frequent manifestations of diarrhea. Postinfectious IBS emerges after a bacter...

Full description

Saved in:

Bibliographic Details
Main Author:	T. A. Ilchishina
Format:	Article
Language:	Russian
Published:	Gastro LLC 2021-10-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	irritable bowel syndrome bismuth tripotassium dicitrate postinfectious ibs diarrhea
Online Access:	https://www.gastro-j.ru/jour/article/view/579
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Modern potential of bismuth in gastroenterology
by: A. A. Sheptulin, et al.
Published: (2010-06-01)

Postinfectious Irritable Bowel Syndrome: Polemic and Open Issues
by: A. A. Sheptulin, et al.
Published: (2022-03-01)

Inflammatory Bowel Diseases and Irritable Bowel Syndrome: Overlap of Two Nosological Forms or Two Variants of the Same Disease?
by: A. A. Sheptulin, et al.
Published: (2019-12-01)

Irritable Bowel Syndrome: What Are the Reasons for Dissatisfaction with the Treatment of Patients and Doctors? (Based on the Experience of Medical Institutions of the Northwestern Federal District of Russia)
by: A. Yu. Baranovsky, et al.
Published: (2024-01-01)

Estimation of cytoprotective effect of bismuth tripotassium dicitrate on gastric mucosa at <i>H. pylori</i> eradication and long-term drug intake
by: A. V. Kononov, et al.
Published: (2014-12-01)

Combination of functional dyspepsia syndrome and irritable bowel syndrome
by: V. T. Ivashkin, et al.
Published: (2011-06-01)

Acetylcholine in irritable bowel syndrome pathogenesis and the role of cholineblockers
by: Yu. O. Shulpekova
Published: (2011-02-01)

Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia
by: V. T. Ivashkin, et al.
Published: (2022-01-01)

Irritable Bowel Syndrome in Terms of Changes in the Microbiota
by: Vladimir T. Ivashkin, et al.
Published: (2019-03-01)

Irritable Bowel Syndrome Diagnosis: Should There Be Alertness to Cancer?
by: A. A. Sheptulin, et al.
Published: (2019-05-01)

Interrelation of irritable bowel syndrome and bacterial overgrowth: is there any?
by: Yu. A. Kucheryavy, et al.
Published: (2014-08-01)

The treatment of irritable bowel syndrome from the modern views on the disease pathogenesis
by: Ye. A. Poluektova, et al.
Published: (2013-03-01)

Features of nervous system in children with irritable bowel syndrome
by: O. K. Botvin’yev, et al.
Published: (2011-12-01)

The Role of the Pathoanatomical Diagnosis «Chronic Gastritis» in the System of Personified Cancer Prevention
by: A. V. Kononov
Published: (2018-09-01)

Pathogenetic Substantiation of the Therapeutic Impact on Microbiota in Irritable Bowel Syndrome
by: Yu. O. Shulpekova, et al.
Published: (2019-09-01)

Discussion of the problem of functional constipation and irritable bowel syndrome in the reports of the International Congress on Neurogastroenterology and Motility (Bologna, 2012)
by: A. A. Sheptulin, et al.
Published: (2013-03-01)

COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship?
by: V. A. Akhmedov
Published: (2022-08-01)

Role of nutritional factors at the irritable bowel syndrome
by: Yu. O. Shulpekova, et al.
Published: (2015-10-01)

Effect of biofeedback – therapy on clinical semiology, quality of life and sensorimotor function of anorectal area at irritable bowel syndrome with refractory constipation
by: O. V. Krapivnaya
Published: (2014-07-01)

Irritable Bowel Syndrome Onset after New Coronavirus Infection COVID-19
by: I. Yu. Feklina, et al.
Published: (2022-03-01)

Issues of diagnostics and treatment of abdominal pain at irritable bowel syndrome at outpatient stage of the healthcare
by: Yu. A. Kucheryavy, et al.
Published: (2015-12-01)

Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19)
by: R. G. Myazin
Published: (2022-05-01)

Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Irritable Bowel Syndrome who Have Suffered COVID-19
by: A. V. Nalyotov, et al.
Published: (2022-09-01)

Esophageal lesions at irritable bowel syndrome
by: M. G. Mnatsakanyan, et al.
Published: (2015-10-01)

Combined alverine citrate and simeticonein preparation in the treatment of irritable bowel syndrome
by: Ye. A. Poluektova, et al.
Published: (2012-07-01)

Pathogenic role of intestinal microflora changes in patients with irritable bowel syndrome and treatment options
by: Ye. A. Poluektova, et al.
Published: (2014-09-01)

Management of a Female Patient with Irritable Bowel Syndrome and Somatoform Disorder
by: E. A. Trush, et al.
Published: (2023-02-01)

Irritable bowel syndrome: pathophysiological and clinical issues
by: V. T. Ivashkin, et al.
Published: (2015-03-01)

Irritable Bowel and Bacterial Overgrowth Syndromes: a Bacterial Link Hypothesis of Functional Disease
by: K. V. Ivashkin, et al.
Published: (2021-04-01)

Single Nucleotide Polymorphisms, Associated with Increased Risk of Irritable Bowel Syndrome with Predominant Constipation: A Meta Analysis
by: E. A. Trush, et al.
Published: (2024-08-01)

Eating Habits, Anxiety and Depression in Patients with Irritable Bowel Syndrome: Clinical and Laboratory Comparisons
by: O. V. Gaus, et al.
Published: (2023-08-01)

Discussion of irritable bowel syndrome issue and functional constipations in reports of the 21st United European Gastroenterological Week (Berlin, 2013)
by: A. A. Sheptulin, et al.
Published: (2014-09-01)

Role of emotional disorders, personality features and disorders of intraceptive sensation in development of somatic symptoms at irritable bowel syndrome
by: Ye. A. Poluektova, et al.
Published: (2013-12-01)

Comparative efficacy of <i>Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus</i> composition and prucalopride in treatment of constipation variant of irritable bowel syndrome
by: V. T. Ivashkin, et al.
Published: (2015-07-01)

Effect of combined therapy by pinaverium bromide and itopride hydrochloride on clinical semiology and quality of life of patients with combination of constipation variant of irritable bowel syndrome and functional dyspepsia
by: O. V. Krapivnaya, et al.
Published: (2015-05-01)

COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA)
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Quality of Life and Level of Physical Activity In Students with and without Symptoms of Functional Dyspepsia and Irritable Bowel Syndrome Surveyed with Questionnaire “7×7” (7 Symptoms Per 7 Days)
by: T. V. Zhestkova
Published: (2020-07-01)

Comparative assessment of <i>Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus</i> and <i>Saccharomyces boulardii</i> efficacy at diarrheal variant of irritable bowel syndrome
by: V. T. Ivashkin, et al.
Published: (2015-05-01)

Dynamics of Somatic and Comorbid Mental Disorders (Distress, Anxiety, Somatisation and Depression) in Patients with Irritable Bowel Syndrome during Therapy with Alimemazine: Results of an Non-Interventional Observational Programme (“Terra”)
by: V. T. Ivashkin, et al.
Published: (2019-01-01)

Determination of Probiotics Prescription Indications in Patients with Irritable Bowel Syndrome (Materials of the Expert Council and Literature Review)
by: V. T. Ivashkin, et al.
Published: (2022-08-01)